Sarepta Therapeutics, Inc., App./cross-res. V. Wa State Health Care Authority, Res./cross-app. ( 2021 )

Filed
Washington State
Court of Appeals
Division Two
October 26, 2021
IN THE COURT OF APPEALS OF THE STATE OF WASHINGTON
DIVISION II
SAREPTA THERAPEUTICS, INC., No. 54870-4-II
Appellant/Cross-Respondent
v.
STATE OF WASHINGTON, HEALTH PUBLISHED OPINION
CARE AUTHORITY, and MARYANNE
LINDEBALD, in her official capacity as
Director of Washington State Health Care
Authority,
Respondent/Cross-Appellant.
LEE, C.J. — Sarepta Therapeutics, Inc., appeals the superior court’s order denying its
petition for judicial review under the Washington Administrative Procedure Act (APA), chapter
34.05 RCW, wherein Sarepta challenged the Washington Health Care Authority’s (HCA)
application of its prior authorization rules to Sarepta’s drug, EXONDYS 51 (Exondys). The HCA
cross-appeals the superior court’s order denying its motion to dismiss Sarepta’s petition for lack
of standing. We hold that Sarepta lacks standing to file its petition for judicial review. Therefore,
the superior court erred by denying the HCA’s motion to dismiss. Accordingly, we reverse the
superior court’s order denying Sarepta’s motion to dismiss for lack of standing and dismiss
Sarepta’s appeal.
No. 54870-4-II
FACTS
A. BACKGROUND—APPROVAL OF EXONDYS
Duchenne Muscular Dystrophy (DMD) is a “genetic disorder characterized by the
progressive loss of skeletal muscle and degeneration.” Clerk’s Papers (CP) at 131. DMD
primarily affects young boys. “The primary symptoms of [DMD] are caused by a lack of
dystrophin in the muscle. Children with [DMD] lose the ability to walk independently and most
become reliant on wheelchairs for mobility by the age of 13.” CP at 131.
On September 19, 2016, the Food and Drug Administration (FDA) approved Sarepta’s new
drug application for Exondys pursuant to its accelerated approval regulations. Exondys is a drug
that treats patients with specific mutations of DMD. “The provision of EXONDYS 51 has been
shown to result in the production of truncated dystrophin, which hopes to have a positive effect on
muscle degeneration [by] slowing or halting the progression of [DMD].” CP at 131 (boldface
omitted). Only 13 percent of all DMD patients have the specific mutation which Exondys treats.
B. MEDICAID DRUG REBATE PROGRAM AND HCA’S PRIOR AUTHORIZATION REQUIREMENT
“Congress created the Medicaid program in 1965 by adding Title XIX to the Social
Security Act.” Pharmaceutical Research & Mfrs. of America v. Walsh, 538 U.S. 644, 650, 123 S.
Ct. 1855, 155 L. Ed. 2d 889 (2003). However, before 1990, Medicaid did not specifically address
outpatient prescription drug coverage. Id. at 651. Instead, the Secretary of the Health and Human
Services would approve individual State plans regulating the coverage of outpatient prescription
drugs as part of controlling Medicaid costs. Id. These individual state plans controlled the
coverage of outpatient prescription drugs through the use of formularies excluding specific drugs
from coverage or through prior authorization requirements. Id. at 651-52.
2
No. 54870-4-II
In 1990, Congress included the Medicaid Drug Rebate Program (MDRP) in the Omnibus
Reconciliation Act of 1990. 42 U.S.C. § 1396r-8; Walsh, 538 U.S. at 652. Under the MDRP, drug
manufacturers must enter into rebate agreements in order for their drugs to be eligible for coverage
by Medicaid. 42 U.S.C. § 1396r-8(a)(1). Once a drug manufacturer enters into a rebate agreement
with either the Secretary or a state, their drugs are considered “covered outpatient drugs” and are
reimbursable under State Medicaid programs. 42 U.S.C. § 1396r-8(a)(1), (k)(2). Reimbursement
for covered outpatient drugs is subject to various limitations. 42 U.S.C. § 1396r-8(d). Congress
specifically included the use of formularies under certain circumstances and the use of prior
authorization programs. 42 U.S.C. § 1396r-8(d)(1), (4), (5).
“A State may subject to prior authorization any covered outpatient drug.” 42 U.S.C. §
1396r-8(d)(1)(A). 42 U.S.C. § 1396r-8(d)(5) provides:
A State plan under this subchapter may require, as a condition of coverage
or payment for a covered outpatient drug . . . the approval of the drug before its
dispensing for any medically accepted indication (as defined in subsection (k)(6))
only if the system providing for such approval—
(A) provides response by telephone or other telecommunication
device within 24 hours of a request for prior authorization; and
(B) except with respect to the drugs on the list referred to in
paragraph (2), provides for the dispensing of at least 72-hour supply of a
covered outpatient prescription drug in an emergency situation (as defined
by the Secretary).
The purpose of creating the MDRP was to reduce the cost of prescription drugs to the
Medicaid program and to ensure that Medicaid recipients had access to a variety of prescription
drug choices:
The Committee believes that Medicaid, the means-tested entitlement program that
purchases basic health care for the poor, should have the benefit of the same
discounts on single source drugs that other large public and private purchasers
enjoy. The Committee bill would therefore establish a rebate mechanism in order
3
No. 54870-4-II
to give Medicaid the benefit of the best price for which a manufacturer sells a
prescription drug to any public or private purchaser. Because the Committee is
concerned that Medicaid beneficiaries have access to the same range of drugs that
the private patients of their physicians enjoy, the Committee bill would require
States that elect to offer prescription drugs to cover all of the products of any
manufacturer that agrees to provide price rebates.
H.R. REP. NO. 101-881 at 96-97 (1990), reprinted in 1990 U.S.C.C.A.N. 2017, 2108-09. The
House Bill report states, “[T]he bill would not affect any authority States have under current law
to impose prior authorization controls on prescription drugs.” 1990 U.S.C.C.A.N. 2017, 2110.
The report further explained,
States that elect to offer prescription drug coverage under their Medicaid
programs would be required to cover all of the drugs of any manufacturer entering
into and complying with such an agreement with the Secretary. This requirement
would take effect April 1, 1991. As under current law, States would have the option
of imposing prior authorization requirements with respect to covered prescription
drugs in order to safeguard against unnecessary utilization and assure that
payments are consistent with efficiency, economy, and quality of care. However,
the Committee does not intend that States establish or implement prior
authorization controls that have the effect of preventing competent physicians from
prescribing in accordance with their medical judgment. This would defeat the
intent of the Committee bill in prohibiting States from excluding coverage of
prescription drugs of manufacturers with agreements—i.e., assuring access by
Medical beneficiaries to prescription drugs where medically necessary.
1990 U.S.C.C.A.N. 2017, 2110. “Congress effectively ratified the Secretary’s practice of
approving state plans containing prior authorization requirements when it created its rebate
program.” Walsh, 583 U.S. at 652.
The legislature has delegated the authority of administering Washington’s Medicaid
program to the HCA. RCW 74.09.530(1)(a). As a part of its administration, the HCA is required
to “take any necessary actions to control costs without reducing the quality of care when
reimbursing for or purchasing drugs.” RCW 70.14.050(1). To further this purpose, the legislature
4
No. 54870-4-II
requires the HCA to establish “an evidence-based prescription drug program.” RCW
70.14.050(1).
The HCA has implemented regulations in the Washington Administrative Code (WACs)
establishing an evidence-based prior authorization program for health care services and equipment,
including prescription drugs.1 WAC 182-501-0165(3). Prior authorization determinations are
based on findings of medical necessity. WAC 182-501-0165(3). Specifically, WAC 182-501-
0165(3) provides that “[t]he [HCA] authorizes, on a case-by-case basis, [prescription drug
requests] when [the HCA] determines the service or equipment is medically necessary as defined
in WAC 182-500-[0]070.” “Medically necessary” is defined as
a term for describing requested service which is reasonably calculated to prevent,
diagnose, correct, cure, alleviate or prevent worsening of conditions in the client
that endanger life, or cause suffering or pain, or result in an illness or infirmity, or
threaten to cause or aggravate a handicap, or cause physical deformity or
malfunction. There is no other equally effective, more conservative or substantially
less costly course of treatment available or suitable for the client requesting the
service. For the purposes of this section, "course of treatment" may include mere
observation or, where appropriate, no medical treatment at all.
WAC 182-500-0070 (medical necessity rule).
Medical necessity determinations are based on submitted medical evidence 2 and an
evidence-based rating system. WAC 182-501-0165(3). The evidence-based rating system is
1
Prescription drugs are considered health care services. WAC 182-501-0050 (“For the purposes
of this section, health care services includes treatment, equipment, related supplies, and drugs.”).
2
The HCA considers the following medical evidence:
(4) The agency reviews available evidence relevant to a medical, dental, or
behavioral health service or equipment to:
(a) Determine its efficacy, effectiveness, and safety;
(b) Determine its impact on health outcomes;
5
No. 54870-4-II
codified under WAC 182-501-0165(6) (hierarchy of evidence rule). Under the hierarchy of
evidence rule, “[t]he [HCA] uses a hierarchy of evidence to determine the weight given to available
data.” WAC 182-501-0165(6)(a). And “[b]ased on the quality of available evidence, the [HCA]
determines if the requested service is effective and safe for the client by classifying it as an ‘A,’
‘B,’ ‘C,’ or ‘D’ level of evidence.” WAC 182-501-0165(6)(b).
An “A” level classification “[s]hows the requested service or equipment is a proven benefit
to the client’s condition.” WAC 182-501-0165(6)(b)(i). A “B” level classification “[s]hows the
requested service or equipment has some proven benefit.” WAC 182-501-0165(6)(b)(ii). A “C”
level classification “[s]hows only weak and inconclusive evidence regarding safety, or efficacy, or
both.” WAC 182-501-0165(6)(b)(iii). And a “D” level classification “[i]s not supported by any
(c) Identify indications for use;
(d) Evaluate pertinent client information;
(e) Compare to alternative technologies; and
(f) Identify sources of credible evidence that use and report evidence-based
information.
(5) The agency considers and evaluates all available clinical information
and credible evidence relevant to the client’s condition. The provider responsible
for the client’s diagnosis, or treatment, or both, must submit with the request
credible evidence specifically related to the client’s condition including, but not
limited to:
(a) A physiological description of the client’s disease, injury, impairment,
or other ailment;
(b) Pertinent laboratory findings;
(c) Pertinent X-ray and/or imaging reports;
(d) Individual patient records pertinent to the case or request;
(e) Photographs, or videos, or both, if requested; and
(f) Objective medical/dental/behavioral health information such as
medically/dentally acceptable clinical findings and diagnoses resulting from
physical or behavioral health examinations.
WAC 182-501-0165(4), (5).
6
No. 54870-4-II
evidence regarding its safety and efficacy, for example that which is considered investigational or
experimental.” WAC 182-501-0165(6)(b)(iv). Based on the evidence classification, the agency:
(i) Approves “A” and “B” rated requests if the service or equipment:
(A) Does not place the client at a greater risk of mortality or morbidity than
an equally effective alternative treatment; and
(B) Is not more costly than an equally effective alternative treatment.
(ii) Approves a “C” rated request only if the provider shows the requested
service is the optimal intervention for meeting the client’s specific condition or
treatment needs, and:
(A) Does not place the client at a greater risk of mortality or morbidity than
an equally effective alternative treatment;
(B) Is less costly to the agency than an equally effective alternative
treatment; and
(C) Is the next reasonable step for the client in a well-documented tried-
and-failed attempt at evidence-based care.
(iii) Denies “D” rated requests unless:
(A) The requested service or equipment has a humanitarian device
exemption from the [FDA]; or
(B) There is a local institutional review board (IRB) protocol addressing
issues of efficacy and safety of the requested service that satisfies both the agency
and the requesting provider.
WAC 182-501-0165(6)(c).
C. HCA’S MEDICAL NECESSITY DETERMINATIONS FOR EXONDYS
In May and June 2019, the HCA received requests for prior authorization for Exondys from
three Medicaid patients with DMD. In June 2019, the HCA denied each of the requests for prior
authorization because it determined that Exondys was not medically necessary for the three
patients. The HCA concluded that Exondys had a level “D” evidence rating and that “[g]iven the
lack of effectiveness noted in the FDA label, the low quality of the clinical trials, an unchanged
trajectory of change for the 6MWT, and continued significant functional decline in multiple
functional domains, the best available evidence does not support the efficacy of and therefore
medical necessity of [Exondys].” CP at 147. In other words, because each of the three Medicaid
7
No. 54870-4-II
patients failed to show clinical responsiveness to Exondys, and because they continued to decline
while taking the drug, the HCA concluded that Exondys was not medically necessary.
On August 27, 2019, the HCA amended its earlier denial letters by changing the evidence
rating of Exondys to “C.” The HCA also explained that the denials were based on each patient’s
failure to show clinical responsiveness to Exondys.
In October 2019, the Medicaid patients’ treating physician requested a peer-to-peer
consultation with the HCA’s medical officer who made the initial medical necessity
determinations. The treating physician provided new information demonstrating that the Medicaid
patients were obtaining minor therapeutic benefits from using Exondys. Based on this information,
the HCA’s medical officer determined that Exondys was medically necessary for the three patients
and provided instructions to the HCA to approve the requests for prior authorization.
D. PROCEDURAL HISTORY
On July 12, 2019, Sarepta filed a petition for judicial review under the APA. Specifically,
Sarepta sought declaratory judgment invalidating the HCA’s hierarchy of evidence rule as it
applies to reimbursement for Exondys.3 Later, Sarepta amended the petition to also include a
challenge to the validity of the medical necessity rule.
The HCA filed a motion to dismiss Sarepta’s petition for judicial review, arguing that
Sarepta lacked standing under the APA. The superior court denied the HCA’s motion to dismiss
for lack of standing. The superior court also denied Sarepta’s petition for judicial review on the
merits.
3
RCW 34.05.570(2)(a) provides, “A rule may be reviewed by petition for declaratory judgment
filed pursuant to this subsection.”
8
No. 54870-4-II
Sarepta appeals and the HCA cross-appeals.
ANALYSIS
The HCA cross-appeals the superior court’s order on the amended petition,4 arguing that
the superior court erred by denying the HCA’s motion to dismiss because Sarepta lacked standing
to bring its petition for judicial review under the APA. We agree.
A. LEGAL PRINCIPLES
We review standing de novo. Center for Biological Diversity v. Dep’t of Fish & Wildlife,
14 Wn. App. 2d 945, 981, 474 P.3d 1107 (2020). The petitioner bears the burden of establishing
standing. KS Tacoma Holdings, LLC v. Shorelines Hr'gs Bd., 166 Wn. App. 117, 127, 272 P.3d
876, review denied, 174 Wn.2d 1007 (2012).
Judicial review of an agency action is governed by the APA. Patterson v. Segale, 171 Wn.
App. 251, 257-58, 289 P.3d 657 (2012). A party has standing to obtain judicial review of an
agency action if that person is aggrieved or adversely affected by the agency action. RCW
34.05.530. A party is aggrieved or adversely affected when three conditions are present:
(1) The agency action has prejudiced or is likely to prejudice that person;
(2) That person's asserted interests are among those that the agency was
required to consider when it engaged in the agency action challenged; and
(3) A judgment in favor of that person would substantially eliminate or
redress the prejudice to that person caused or likely to be caused by the agency
action.
4
The HCA’s cross-appeal alleges that the superior court erred by denying its motion to dismiss
of lack of standing. Because standing is required for a party to obtain judicial review under the
APA, we address the HCA’s cross-appeal before Sarepta’s appeal on the merits of the petition.
See RCW 34.05.530.
9
No. 54870-4-II
RCW 34.05.530(1)-(3).5 All three requirements must be established for a person to have standing.
Allan v. Univ. of Wash., 140 Wn.2d 323, 326-27, 997 P.2d 360 (2000).
The first and third requirements of this standing test are collectively referred to as the
“‘injury-in-fact’ test.” Patterson, 171 Wn. App. at 258 (quoting Allan, 140 Wn.2d at 327). Under
the “injury-in-fact” test, the petitioner must show that the agency decision caused some specific
and perceptible harm. Freedom Found. v. Bethel School Dist., 14 Wn. App. 2d 75, 86, 469 P.3d
364 (2020), review denied, 196 Wn.2d 1033 (2021). In other words, there must be an invasion of
a legally protected interest. Snohomish County Pub. Transp. Benefit Area v. Pub. Emp't Relations
Comm'n, 173 Wn. App. 504, 513, 294 P.3d 803 (2013).
Where “a party alleges a threatened injury, ‘as opposed to an existing injury,’ the party
must prove that the threatened injury is ‘immediate, concrete, and specific’” in order to have
standing under the APA. City of Burlington v. Liquor Control Bd., 187 Wn. App. 853, 869, 351
P.3d 875, review denied, 184 Wn.2d 1014 (2015) (quoting Trepanier v. City of Everett, 64 Wn.
App. 380, 383, 824 P.2d 524 (1992)). “Conjectural or hypothetical injuries are insufficient to
confer standing.” Freedom Found., 14 Wn. App. 2d at 86. Finally, the petitioner must show that
5
In addition to the standing requirements under RCW 34.05.530, RCW 34.05.570(2)(b)(i)
requires a person challenging an agency rule to show that the rule or its threatened application
“interferes with or impairs or immediately threatens to interfere with or impair the legal rights or
privileges of the petitioner.” Furthermore, challenges to agency rules are brought through a
declaratory judgment action. RCW 34.05.570(2)(a). A justiciable controversy is required to bring
a declaratory judgment action. To-Ro Trade Shows v. Collins, 144 Wn.2d 403, 410-11, 27 P.3d
1149 (2001), cert. denied, 535 U.S. 931 (2002). A justiciable controversy requires (1) an actual,
present, and existing dispute, (2) between parties with opposing interests, (3) involving direct and
substantial interests, and (4) for which a judicial determination will be final and conclusive. Id. at
411. Neither party argues these additional standards should apply or that they would compel a
different result. And under any of the applicable standards, Sarepta has failed to establish standing
to bring this action challenging the HCA’s rules.
10
No. 54870-4-II
a favorable decision will likely—not merely speculatively—redress the injury. Patterson, 171
Wn. App. at 259.
The second requirement is referred to as the “zone of interests” test. Allan, 140 Wn.2d at
327. “The zone of interest test limits judicial review of an agency action to litigants with a viable
interest at stake, rather than individuals with only an attenuated interest in the agency action.” City
of Burlington, 187 Wn. App. at 862. In order to satisfy the “zone of interests” test, the party
seeking standing must demonstrate that “the Legislature intended the agency to protect the party's
interests when taking the action at issue.” St. Joseph Hosp. and Health Care Ctr. v. Dep’t of
Health, 125 Wn.2d 733, 739-40, 887 P.2d 891 (1995); City of Burlington, 187 Wn. App. at 863.
B. SAREPTA’S STANDING—ZONE OF INTERESTS
The HCA argues that Sarepta fails to establish standing because Sarepta has not met its
burden to show that the zone of interests test is satisfied. Specifically, the HCA contends that the
legislature did not intend to protect a drug manufacturer’s financial interests in establishing the
administration of Washington’s Medicaid program. Sarepta argues that because it has entered a
Medicaid Drug Rebate Agreement under the MDRP, its interest in having its drugs reimbursed by
the HCA is established under the terms of the MDRP. We agree with the HCA.
As an initial matter, the Washington legislature clearly did not intend to protect the interests
of drug manufacturers when it directed the HCA to establish an evidence-based prescription drug
program under RCW 70.14.050. The legislature directed the HCA to “take any necessary actions
to control costs without reducing the quality of care when reimbursing for or purchasing drugs.”
RCW 70.14.050(1). Based on the plain language of the statute, the legislature’s intent was for the
HCA to balance controlling costs with ensuring quality of care. The legislature did not intend for
11
No. 54870-4-II
the HCA to protect Sarepta’s financial interests when making rules to administer the prescription
drug program. Therefore, Sarepta has failed to satisfy the zone of interests test under the
Washington statutes. See St. Joseph Hosp., 125 Wn.2d at 739-40.
However, Sarepta argues that its standing derives from the MDRP, not the Washington
statutes. Sarepta contends that the MDRP guarantees coverage when a drug manufacturer enters
into a rebate agreement under the terms of the MDRP. Because the HCA is responsible for
ensuring the state Medicaid program complies with federal Medicaid requirements, Sarepta asserts
that the HCA was required to protect Sarepta’s interests under the MDRP when administering its
prescription drug program.
Sarepta misinterprets the effect of an agreement under the MDRP and conflates coverage
of drugs with reimbursement of drugs. And Sarepta’s argument fails to acknowledge Congress’s
legislative intent when establishing the MDRP. Sarepta’s financial interests are no more protected
under the MDRP than they are under RCW 70.14.050. Because Congress did not intend for
prescription drug programs to protect the financial interests of drug manufacturers, Sarepta is not
within the zone of interests protected by the MDRP.
First, Sarepta’s argument fails to acknowledge Congress’s legislative intent when
establishing the MDRP. The text of the MDRP does not contain an explicit statement of purpose
or intent like that contained in RCW 70.14.050. Therefore, the plain language of the statute is
ambiguous in establishing Congress’s intent in passing the legislation. However, the legislative
history is not ambiguous. The house bill report clearly shows that Congress’s intent in establishing
the MDRP was to control Medicaid costs by reducing the costs of prescription drugs. 1990
U.S.C.C.A.N. 2017, 2108 (“The Committee believes that Medicaid, the means-tested entitlement
12
No. 54870-4-II
program that purchases basic health care for the poor, should have the benefit of the same discounts
on single source drugs that other large public and private purchasers enjoy.”). Congress further
intended to ensure Medicaid patients have access to the same range of drugs as patients that do not
require Medicaid. 1990 U.S.C.C.A.N. 2017, 2108-09. The legislative history of the MDRP does
not establish Congress’s intent to protect the drug manufacturer’s financial interests when
establishing the MDRP.
Second, despite Congressional intent, Sarepta argues that agreements under the MDRP
entitle Sarepta to reimbursement for its drugs, which creates a protected interest for drug
companies who have agreements under the MDRP. Sarepta’s argument conflates the concepts of
coverage and reimbursement under the MDRP. Furthermore, Sarepta’s argument misrepresents
the effect of a rebate agreement under the MDRP.
Sarepta’s argument is that because state prescription drug programs are required to cover
all of a drug manufacturer’s prescription drugs, the state prescription drug program is required to
pay for all covered drugs prescribed for its intended use. This is an incorrect reading of the MDRP.
The MDRP does not specifically define the meaning of “covered” and the definition of a
“covered outpatient drug” does not contain any language related to reimbursement or payment for
a drug. See 42 U.S.C. § 1396r-8(k)(2). However, reading the MDRP as a whole shows there is a
difference between coverage of a drug and reimbursement/payment for a drug. For example, 42
U.S.C. § 1396 r-8(d)(5) references prior authorization as a condition of “coverage or payment,”
indicating that there is a difference between coverage of a drug and payment for a drug. Sections
of the MDRP also reference “upper payment limits” and “maximum allowable cost limitation”
established by State programs, implying that there is a point at which the State would not be
13
No. 54870-4-II
required to pay for covered drugs. See 42 U.S.C. § 1396r-8(e)(3) (“This section shall not supersede
or affect provisions . . . relating to any maximum allowable cost limitation established by a State
for payment by the State for covered outpatient drugs, and rebates shall be made under this section
without regard to whether or not payment by the State for such drugs is subject to such a limitation
or the amount of such a limitation.”); see also 42 U.S.C. § 1396r-8(e)(4), (e)(5).
The language of the MDRP does not establish that coverage for prescription drugs requires
payment for prescription drugs. The MDRP only establishes that the covered prescription drugs
are eligible for reimbursement or payment under Medicaid programs. Therefore, Sarepta has
incorrectly interpreted the MDRP to guarantee payment for prescription drugs; the MDRP only
allows coverage for prescription drugs.
Third, Sarepta argues that its agreement under the MDRP creates an interest that must be
protected because drug manufacturers agree to provide rebates in exchange for a guarantee that
that State Medicaid programs cover their drugs. As explained above, coverage is not the same as
payment. And rebate agreements under the MDRP are not the equivalent of negotiated contracts
as Sarepta implies. Rebate agreements under the MDRP are a mandatory prerequisite for
prescription drugs to be eligible for Medicaid coverage. 42 U.S.C. § 1396r-8(a)(1). In other words,
to the extent that a rebate agreement is akin to a contract, drug manufacturers enter into rebate
agreements in exchange for their drugs being eligible for Medicaid coverage, not to guarantee
payment for their drugs.
Because the MDRP only makes the drugs covered and does not guarantee drug
manufacturers payment for their drugs under Medicaid, the MDRP does not establish that Sarepta
has an interest that the HCA was required to protect when it established rules for the administration
14
No. 54870-4-II
of its Medicaid prescription drug program. Therefore, Sarepta has failed to establish that the
MDRP places Sarepta’s financial interests within the zone of interests required to be considered
by the HCA.
Sarepta’s MDRP agreement does not establish standing to petition for judicial review under
the APA. Therefore, Sarepta has failed to establish standing under the APA to bring its petition
for judicial review of the HCA’s application of its hierarchy of evidence rule in determining
reimbursement for Exondys.
CONCLUSION
Sarepta does not have standing to petition for judicial review of HCA’s prior authorization
rules under the APA because Sarepta has failed to satisfy the zone of interests requirement.
Therefore, the superior court erred by denying the HCA’s motion to dismiss for lack of standing.
Accordingly, we reverse the superior court’s order denying the HCA’s motion to dismiss for lack
of standing and dismiss Sarepta’s appeal.
Lee, C.J.
We concur:
Maxa, J.
Cruser, J.
15